LIN-001

N/A

Report date: 2025/01/26 15:44:57

Base Information

Drug NameLIN-001
Drug Alias Name89Zr-DFO-Lx-trastuzumabtrastuzumab-Lx-DFO-89ZrLIN-001
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 modulators
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryNetherlands
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesLinXis BV
China Registration ClassN/A

Develop Information

Active CompaniesLinXis BVVu University Medical Center
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A